| Variables | Global n = 40 | BCR1 after prostatectomy n = 30 | BCR1 after radiotherapy n = 10 |
| Age (years) | 66.5 (48 - 78) | 65.50 (48 - 72) | 71 (58 - 78) |
| PSA2 at diagnosis (ng/mL) | 7.08 (5 - 13.6) | 6.89 (4.14 - 45.83) | 10.07 (4.62 - 55.65) |
| Stage |
|
|
|
| II | 46.2% | 55.2% | 20% |
| III | 46.2% | 34.5% | 80% |
| IVa | 7.7% | 10.3% |
|
| ISUP3 |
|
|
|
| 1 | 22.5% | 16.7% | 40% |
| 2 | 25% | 26.7% | - |
| 3 | 30% | 40% | 20% |
| 4 | 7.5% | 6.7% | 10% |
| 5 | 15% | 10% | 30% |
| D’Amico risk |
|
|
|
| Intermediate risk | 17.5% | 20% | 10% |
| High risk | 82.5% | 80% | 90% |
| 1st treatment |
|
|
|
| Surgery | 75% | 100% | - |
| EBRT4 | EBRT4 22.5% EBRT4 + BT5 2.5% |
| EBRT4 90% EBRT4 + BT5 10% |
| Hormonal therapy |
|
|
|
| Yes | 20% | - | 80% |
| No | 80% | - | 20% |
| Time HT6 (months) |
|
|
|
| 12 months | - | - | 12.5% |
| 24 months | - | - | 87.5% |
| Surgical margins |
|
|
|
| Positive | 37.5% | 15 (50%) | - |
| Negative | 37.5% | 15 (50%) | - |
| BCR1-free interval (months) | 20.5 (1 - 162) | 17 (1 - 118) | 85.5 (12 - 162) |
| PSA2 doubling time (months) | 9.78 (1.31 - 75.45) | 7.61 (1.51 - 33.25) | 12 (0.9 - 60.85) |
| Comorbidities |
|
|
|
| Diabetes mellitus | 17.5% | 20% | 10% |
| Arterial hypertension | 62.5% | 60% | 70% |
| Dyslipidemia | 50% | 60% | 20% |
| Cardiological | 20% | 20% | 20% |